MRNA Stock: Moderna, Inc. Stock Price, Analysis & Insights
Get live mrna stock price $24.54, comprehensive Moderna, Inc. stock analysis, charts, news, and expert forecast. Real-time mrna stock data and investment insights.
Loading chart...
Company Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Company Information
- CEO
- Stephane Bancel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5800
Contact Information
- Website
- https://www.modernatx.com
- Address
- 200 Technology Square
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Moderna, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Stephane Bancel, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Moderna, Inc. competes in the Biotechnology within the broader Healthcare. With 9.6 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Moderna, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Moderna, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Moderna, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Moderna, Inc.
- ⚠Investors should consider how Moderna, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
9.57B
P/E Ratio
-3.04
Beta
1.11
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 9.57B market capitalization
- Trading Volume: 10.32M shares traded today
- Price Range: 52-week range of $23.04 - $48.92
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Moderna, Inc.
Moderna, Inc. (MRNA) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 9.57B, the company represents a significant player in its market. The stock is currently trading at $24.54 with a positivedaily change of 0.86%.
The company's 5800 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -3.04, beta of 1.11, and 52-week price range from $23.04 to $48.92when evaluating investment opportunities.
Why Invest in Moderna, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Stephane Bancel
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.